Global Intravenous Immunoglobulins Market Overview And Scope:
Global Intravenous Immunoglobulins Market Size was estimated at USD 10326.77 million in 2022 and is projected to reach USD 14614.76 million by 2028, exhibiting a CAGR of 5.96% during the forecast period.
The Global Intravenous Immunoglobulins Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Intravenous Immunoglobulins utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: CSL Behring, Grifols, Octapharma, Takeda, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Sanquin
Global Intravenous Immunoglobulins Market Segmentation
By Type, Intravenous Immunoglobulins market has been segmented into:IgG
IgA
IgM
IgE
IgD
By Application, Intravenous Immunoglobulins market has been segmented into:
Primary Immunodeficiency
Idiopathic Thrombocytopenic Purpura
Chronic Inflammatory Demyelinating Polyneuropathy
Kawasaki Disease
Guillain-Barre Syndrome
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Intravenous Immunoglobulins market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Intravenous Immunoglobulins market.
Top Key Players Covered in Intravenous Immunoglobulins market are:
CSL Behring
Grifols
Octapharma
Takeda
ADMA Biologics
Bayer
Bharat Serum and Vaccines
Biotest
China Biologic Products
Hualan Biological Engineering
Kedrion Biopharma
LFB Group
Sanquin
Objective to buy this Report:
1. Intravenous Immunoglobulins analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Intravenous Immunoglobulins market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Intravenous Immunoglobulins Market by Type
5.1 Intravenous Immunoglobulins Market Overview Snapshot and Growth Engine
5.2 Intravenous Immunoglobulins Market Overview
5.3 IgG
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 IgG: Geographic Segmentation
5.4 IgA
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 IgA: Geographic Segmentation
5.5 IgM
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 IgM: Geographic Segmentation
5.6 IgE
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 IgE: Geographic Segmentation
5.7 IgD
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 IgD: Geographic Segmentation
Chapter 6: Intravenous Immunoglobulins Market by Application
6.1 Intravenous Immunoglobulins Market Overview Snapshot and Growth Engine
6.2 Intravenous Immunoglobulins Market Overview
6.3 Primary Immunodeficiency
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Primary Immunodeficiency: Geographic Segmentation
6.4 Idiopathic Thrombocytopenic Purpura
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Idiopathic Thrombocytopenic Purpura: Geographic Segmentation
6.5 Chronic Inflammatory Demyelinating Polyneuropathy
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Chronic Inflammatory Demyelinating Polyneuropathy: Geographic Segmentation
6.6 Kawasaki Disease
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Kawasaki Disease: Geographic Segmentation
6.7 Guillain-Barre Syndrome
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Guillain-Barre Syndrome: Geographic Segmentation
6.8 Others
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2017-2032F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Intravenous Immunoglobulins Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Intravenous Immunoglobulins Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Intravenous Immunoglobulins Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CSL BEHRING
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 GRIFOLS
7.4 OCTAPHARMA
7.5 TAKEDA
7.6 ADMA BIOLOGICS
7.7 BAYER
7.8 BHARAT SERUM AND VACCINES
7.9 BIOTEST
7.10 CHINA BIOLOGIC PRODUCTS
7.11 HUALAN BIOLOGICAL ENGINEERING
7.12 KEDRION BIOPHARMA
7.13 LFB GROUP
7.14 SANQUIN
Chapter 8: Global Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 IgG
8.2.2 IgA
8.2.3 IgM
8.2.4 IgE
8.2.5 IgD
8.3 Historic and Forecasted Market Size By Application
8.3.1 Primary Immunodeficiency
8.3.2 Idiopathic Thrombocytopenic Purpura
8.3.3 Chronic Inflammatory Demyelinating Polyneuropathy
8.3.4 Kawasaki Disease
8.3.5 Guillain-Barre Syndrome
8.3.6 Others
Chapter 9: North America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 IgG
9.4.2 IgA
9.4.3 IgM
9.4.4 IgE
9.4.5 IgD
9.5 Historic and Forecasted Market Size By Application
9.5.1 Primary Immunodeficiency
9.5.2 Idiopathic Thrombocytopenic Purpura
9.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
9.5.4 Kawasaki Disease
9.5.5 Guillain-Barre Syndrome
9.5.6 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 IgG
10.4.2 IgA
10.4.3 IgM
10.4.4 IgE
10.4.5 IgD
10.5 Historic and Forecasted Market Size By Application
10.5.1 Primary Immunodeficiency
10.5.2 Idiopathic Thrombocytopenic Purpura
10.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
10.5.4 Kawasaki Disease
10.5.5 Guillain-Barre Syndrome
10.5.6 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 IgG
11.4.2 IgA
11.4.3 IgM
11.4.4 IgE
11.4.5 IgD
11.5 Historic and Forecasted Market Size By Application
11.5.1 Primary Immunodeficiency
11.5.2 Idiopathic Thrombocytopenic Purpura
11.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
11.5.4 Kawasaki Disease
11.5.5 Guillain-Barre Syndrome
11.5.6 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 IgG
12.4.2 IgA
12.4.3 IgM
12.4.4 IgE
12.4.5 IgD
12.5 Historic and Forecasted Market Size By Application
12.5.1 Primary Immunodeficiency
12.5.2 Idiopathic Thrombocytopenic Purpura
12.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
12.5.4 Kawasaki Disease
12.5.5 Guillain-Barre Syndrome
12.5.6 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 IgG
13.4.2 IgA
13.4.3 IgM
13.4.4 IgE
13.4.5 IgD
13.5 Historic and Forecasted Market Size By Application
13.5.1 Primary Immunodeficiency
13.5.2 Idiopathic Thrombocytopenic Purpura
13.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
13.5.4 Kawasaki Disease
13.5.5 Guillain-Barre Syndrome
13.5.6 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Intravenous Immunoglobulins Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 IgG
14.4.2 IgA
14.4.3 IgM
14.4.4 IgE
14.4.5 IgD
14.5 Historic and Forecasted Market Size By Application
14.5.1 Primary Immunodeficiency
14.5.2 Idiopathic Thrombocytopenic Purpura
14.5.3 Chronic Inflammatory Demyelinating Polyneuropathy
14.5.4 Kawasaki Disease
14.5.5 Guillain-Barre Syndrome
14.5.6 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Intravenous Immunoglobulins Scope:
|
Report Data
|
Intravenous Immunoglobulins Market
|
|
Intravenous Immunoglobulins Market Size in 2025
|
USD XX million
|
|
Intravenous Immunoglobulins CAGR 2025 - 2032
|
XX%
|
|
Intravenous Immunoglobulins Base Year
|
2024
|
|
Intravenous Immunoglobulins Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
CSL Behring, Grifols, Octapharma, Takeda, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, Sanquin.
|
|
Key Segments
|
By Type
IgG
IgA
IgM
IgE
IgD
By Applications
Primary Immunodeficiency
Idiopathic Thrombocytopenic Purpura
Chronic Inflammatory Demyelinating Polyneuropathy
Kawasaki Disease
Guillain-Barre Syndrome
Others
|
